Could vimseltinib be the next big thing in TGCT treatment? FDA says Yes!
The U.S. Food and Drug Administration (FDA) has granted priority review status to Deciphera Pharmaceuticals, Inc.'s New Drug Application (NDA) for vimseltinib, a drug developed ... Read More
FDA extends review period for Humacyte’s vascular trauma treatment ATEV
The U.S. Food and Drug Administration’s review of Humacyte, Inc.'s innovative vascular trauma treatment, known as the acellular tissue engineered vessel (ATEV), has hit an ... Read More
Spectrum Pharmaceuticals seeks FDA approval for ROLONTIS to combat chemotherapy-induced neutropenia
In a significant move within the oncology sector, Spectrum Pharmaceuticals has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) ... Read More
Teva secures FDA approval for Ajovy injection in migraine prevention
Teva Pharmaceutical Industries has achieved a significant regulatory milestone with the U.S. Food and Drug Administration (FDA) approving Ajovy (fremanezumab-vfrm) injection for migraine prevention in ... Read More